Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
The aim of this study was to investigate the relationship between whole-tumor CT perfusion and FDG PET/CT parameters in non-small cell lung cancer (NSCLC).
To compare lung injury among non-small cell lung cancer (NSCLC) patients treated with IMRT or proton therapy as revealed by <sup>18</sup>F-FDG post-treatment uptake and to determine factors predictive for clinically symptomatic radiation pneumonitis.
During the last week of CRT, routine assessment of moderate-to-severe RP-related symptoms provides a simple way to identify patients with NSCLC who may be at risk for developing significant post-CRT RP, especially when PET/CT images of normal-lung FDG uptake are not available.
A Phase 2 study was conducted to compare <sup>18</sup>F-FDG PET/CT and <sup>99m</sup>Tc-EC-G SPECT/CT in the detection and staging of patients with non-small cell lung cancer (NSCLC).
We analysed a correlation between pre- to post-treatment primary tumour metabolic volume (PT-MV) reduction on 18F-FDG-PET/CT and survival in non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy (CRT).
Two patient cohorts were retrospectively collected into a dataset of 341 <sup>18</sup>F-labeled 2-deoxy-2fluoro-d-glucose ([<sup>18</sup>F] FDG) PET-CT images of NSCLC tumours (125 ADC, 174 SqCC, and 42 cases with unknown subtype).
<sup>18</sup>F-FDG PET/MRI and <sup>18</sup>F-FDG PET/CT show an equivalently high diagnostic performance for T and N staging in patients suffering from NSCLC.
The prognostic value of metabolic parameters using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has not been established for early non-small cell lung cancer (NSCLC).
This review outlines the most recent literature on developments in FDG PET imaging for prognostication and radiotherapy target volume delineation (TVD) in NSCLC.
EGFR-TKI treatment sensitivity prediction in NSCLC using <sup>18</sup> F-FDG PET/CT imaging significantly correlated with CD147-mediated glucose metabolic regulation via the Akt/mTOR-dependent pathway.
A Pilot Study of Texture Analysis of Primary Tumor [<sup>18</sup>F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer.
To determine the heterogeneity of glucose uptake applying fractal analysis on positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) images in patients with non-small cell lung carcinoma (NSCLC) before surgery, and to assess whether this heterogeneity was associated with disease-free survival (DFS).
The present study aims to assess the performance of 18F-FDG PET-CT on mediastinal staging of non-small cell lung cancer (NSCLC) in a location with endemic granulomatous infectious disease.
MTV of baseline 4DST PET/CT along with MTV of baseline FDG PET/CT represent promising predictors of PFS, and MTV of baseline 4DST PET/CT along with MTV and TLG of baseline FDG PET/CT are possible predictors of OS in patients with advanced NSCLC.
Finally, to distinguish between benign and malignant lesions [<sup>68</sup>Ga]SFITGv6 was applied as radiotracer for PET/x-ray computed tomography (CT) imaging of NSCLC patients with unclear diagnosis upon routinely performed 2-deoxy-2-[<sup>18</sup>F]flouro-D-glucose ([<sup>18</sup>F]FDG)-PET/CT.
There is a growing interest in using <sup>18</sup>F-FDG PET for therapy response assessment in NSCLC which relies on quantitative PET parameters such as standardized uptake values (SUV).